SG11202104192TA - Combination of small molecule cd-47 inhibitors with other anti-cancer agents - Google Patents
Combination of small molecule cd-47 inhibitors with other anti-cancer agentsInfo
- Publication number
- SG11202104192TA SG11202104192TA SG11202104192TA SG11202104192TA SG11202104192TA SG 11202104192T A SG11202104192T A SG 11202104192TA SG 11202104192T A SG11202104192T A SG 11202104192TA SG 11202104192T A SG11202104192T A SG 11202104192TA SG 11202104192T A SG11202104192T A SG 11202104192TA
- Authority
- SG
- Singapore
- Prior art keywords
- inhibitors
- combination
- small molecule
- cancer agents
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201841042108 | 2018-11-08 | ||
| PCT/IB2019/059602 WO2020095256A1 (en) | 2018-11-08 | 2019-11-08 | Combination of small molecule cd-47 inhibitors with other anti-cancer agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202104192TA true SG11202104192TA (en) | 2021-05-28 |
Family
ID=69159806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202104192TA SG11202104192TA (en) | 2018-11-08 | 2019-11-08 | Combination of small molecule cd-47 inhibitors with other anti-cancer agents |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11311517B2 (en) |
| EP (1) | EP3876931A1 (en) |
| JP (1) | JP2022507025A (en) |
| KR (1) | KR20210088584A (en) |
| CN (1) | CN112930181A (en) |
| AU (1) | AU2019375193A1 (en) |
| BR (1) | BR112021008781A2 (en) |
| CA (1) | CA3118843A1 (en) |
| EA (1) | EA202190776A1 (en) |
| IL (1) | IL282972A (en) |
| MX (1) | MX2021005240A (en) |
| PH (1) | PH12021550832A1 (en) |
| SG (1) | SG11202104192TA (en) |
| WO (1) | WO2020095256A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019138367A1 (en) * | 2018-01-12 | 2019-07-18 | Aurigene Discovery Technologies Limited | 1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways |
| JP2024508395A (en) * | 2021-02-10 | 2024-02-27 | グレート ノベル セラピューティクス バイオテック アンド メディカルズ コーポレイション | Pharmaceutical combinations and methods for stimulating immune responses against cancer or overcoming immunosuppression |
| CN113018415B (en) * | 2021-03-17 | 2022-07-01 | 遵义医科大学 | Medicine composition and application thereof |
| CN113750215B (en) * | 2021-09-24 | 2023-06-23 | 暨南大学 | Combination for the treatment of tumors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2788848T3 (en) | 2013-09-06 | 2020-10-23 | Aurigene Discovery Tech Ltd | 1,2,4-Oxadiazole derivatives as immunomodulators |
| EA034708B1 (en) * | 2015-03-10 | 2020-03-10 | Ауриджен Дискавери Текнолоджис Лимитед | 1,2,4-oxadiazole and thiadiazole compounds as immunomodulators |
| CA2979161A1 (en) | 2015-03-10 | 2016-09-15 | Aurigene Discovery Technologies Limited | 3-substituted-1,2,4-oxadiazole and thiadiazole compounds as immunomodulators |
| CN107454838A (en) | 2015-04-14 | 2017-12-08 | 宝洁公司 | Solid care composition |
| CN104804093A (en) | 2015-05-27 | 2015-07-29 | 江苏春申堂药业有限公司 | Single-domain antibody for CD47 |
| JP2018535692A (en) | 2015-09-21 | 2018-12-06 | エラスムス ユニバーシティ メディカル センターＥｒａｓｍｕｓ Ｕｎｉｖｅｒｓｉｔｙ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ | Anti-CD47 antibody and method of use |
| EP3243522A1 (en) | 2016-05-10 | 2017-11-15 | Université Pierre et Marie Curie (Paris 6) | Agonist agents of cd47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death |
| US11759496B2 (en) | 2016-05-10 | 2023-09-19 | Philippe Karoyan | Compounds and pharmaceutical use thereof in the treatment of cancer |
| WO2018047139A1 (en) * | 2016-09-12 | 2018-03-15 | Aurigene Discovery Technologies Limited | Compounds as modulators of tigit signalling pathway |
| US20200061030A1 (en) * | 2016-10-20 | 2020-02-27 | Aurigene Discovery Technologies Limited | Dual inhibitors of vista and pd-1 pathways |
| WO2019138367A1 (en) * | 2018-01-12 | 2019-07-18 | Aurigene Discovery Technologies Limited | 1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways |
| US20210379024A1 (en) * | 2018-03-14 | 2021-12-09 | Aurigene Discovery Technologies Limited | Method of modulating tigit and pd-1 signalling pathways using 1,2,4-oxadiazole compounds |
-
2019
- 2019-11-08 BR BR112021008781-8A patent/BR112021008781A2/en unknown
- 2019-11-08 MX MX2021005240A patent/MX2021005240A/en unknown
- 2019-11-08 WO PCT/IB2019/059602 patent/WO2020095256A1/en unknown
- 2019-11-08 JP JP2021524166A patent/JP2022507025A/en active Pending
- 2019-11-08 EA EA202190776A patent/EA202190776A1/en unknown
- 2019-11-08 KR KR1020217014395A patent/KR20210088584A/en active Search and Examination
- 2019-11-08 EP EP19835717.0A patent/EP3876931A1/en active Pending
- 2019-11-08 CA CA3118843A patent/CA3118843A1/en active Pending
- 2019-11-08 US US16/678,594 patent/US11311517B2/en active Active
- 2019-11-08 CN CN201980071532.5A patent/CN112930181A/en active Pending
- 2019-11-08 SG SG11202104192TA patent/SG11202104192TA/en unknown
- 2019-11-08 AU AU2019375193A patent/AU2019375193A1/en active Pending
-
2021
- 2021-04-13 PH PH12021550832A patent/PH12021550832A1/en unknown
- 2021-05-05 IL IL282972A patent/IL282972A/en unknown
-
2022
- 2022-04-25 US US17/728,325 patent/US20220241248A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020095256A1 (en) | 2020-05-14 |
| EP3876931A1 (en) | 2021-09-15 |
| EA202190776A1 (en) | 2021-09-20 |
| MX2021005240A (en) | 2021-06-18 |
| US11311517B2 (en) | 2022-04-26 |
| IL282972A (en) | 2021-06-30 |
| KR20210088584A (en) | 2021-07-14 |
| AU2019375193A1 (en) | 2021-05-13 |
| BR112021008781A2 (en) | 2021-08-03 |
| PH12021550832A1 (en) | 2021-10-04 |
| US20220241248A1 (en) | 2022-08-04 |
| US20200147054A1 (en) | 2020-05-14 |
| CA3118843A1 (en) | 2020-05-14 |
| CN112930181A (en) | 2021-06-08 |
| JP2022507025A (en) | 2022-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275089A (en) | Polycyclic compounds as allosteric shp2 inhibitors | |
| IL283267B (en) | Inhibitors of the menin-mll interaction | |
| IL268031B (en) | Pyridine compounds as allosteric shp2 inhibitors | |
| HK1250959A1 (en) | Nitrobenzyl derivatives of anti-cancer agents | |
| IL261557A (en) | Small molecule ire1-alpha inhibitors | |
| IL259560A (en) | Inhibitors of the menin-mll interaction | |
| PL3512850T3 (en) | Inhibitors of the menin-mll interaction | |
| ZA201904615B (en) | Small molecule inhibitors of the jak family of kinases | |
| IL282972A (en) | Combination of small molecule cd-47 inhibitors with other anti-cancer agents | |
| IL289754A (en) | Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents | |
| IL281634A (en) | N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as ccr6 inhibitors | |
| IL260720B (en) | Inhibitors of the orexin-1 receptor and compositions comprising the same | |
| DK3240767T3 (en) | MICROCAPE-LEADED NITRIFICATION INHIBITOR COMPOSITIONS | |
| DK3137437T3 (en) | MICROCRAINED NITRIFICATION INHIBITOR COMPOSITION | |
| IL281949A (en) | Small molecule menin inhibitors | |
| GB201708457D0 (en) | Inhibitors of metallo-beta-lactamases | |
| IL276312B1 (en) | Use of alkoxypyrazoles as nitrification inhibitors | |
| IL283433A (en) | Ire1 small molecule inhibitors | |
| GB201708451D0 (en) | Inhibitors of metallo-beta-lactamases | |
| ITUA20161994A1 (en) | USE OF DDX3 INHIBITORS AS ANTI-HYPER-PERFORMANCE AGENTS | |
| DK3595442T3 (en) | MICROCAPE-LEADED NITRIFICATION INHIBITOR COMPOSITIONS | |
| DK3436047T3 (en) | Dual Ace-C-Domain Inhibitors | |
| IL291396A (en) | Mll1 inhibitors and anti-cancer agents | |
| GB201720445D0 (en) | Use of TRPV1 agonists | |
| GB201620933D0 (en) | Use of TRPV1 agonists |